ClinicalTrials.Veeva

Menu
H

Highland Medical P.C. | Hematology Oncology Associates of Rockland

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Pembrolizumab
Everolimus
Carboplatin
Ibrutinib
Xentuzumab
Paclitaxel
ASA404
cyclophosphamide
Ixabepilone
Vinorelbine

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 20 total trials

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physici...

Enrolling
Breast Neoplasms
Drug: Liposomal doxorubicin
Drug: Sacituzumab tirumotecan

The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing o...

Enrolling
Small Lymphocytic Lymphoma
Leukemia, Lymphocytic, Chronic, B-Cell
Drug: Venetoclax
Drug: Ibrutinib

A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer.

Enrolling
Advanced Breast Cancer
Drug: ARV-471
Drug: Fulvestrant

The main purpose of this study is to evaluate the efficacy and safety of M281 in participants with warm autoimmune hemolytic anemia (wAIHA).

Enrolling
Warm Autoimmune Hemolytic Anemia
Drug: M281
Drug: Placebo

The purpose of this study is to assess the efficacy and safety of co-formulated pembrolizumab/quavonlimab versus other treatments in participants wit...

Active, not recruiting
Colorectal Cancer
Biological: MK-4830
Biological: Pembrolizumab/Quavonlimab

This is a Phase 2, open-label, multicenter, multiple subcutaneous injection, safety and efficacy study of PF-06835375 in adult participants with prim...

Enrolling
Primary Immune Thrombocytopenia
Biological: PF-06835375

The safety and efficacy of pembrolizumab plus the investigator's choice of chemotherapy will be assessed compared to placebo plus the investigator's...

Active, not recruiting
Breast Neoplasms
Drug: dextrose
Drug: liposomal doxorubicin

Trial sponsors

Merck Sharp & Dohme (MSD) logo
Janssen (J&J Innovative Medicine) logo
Pfizer logo
Boehringer Ingelheim logo
H
H
Incyte logo
Merck KGaA (EMD Serono) logo
Merck KGaA (EMD Serono) logo
Novartis logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems